Key result
Elevated ACE2 (p=0.04 vs mild) and lower angiotensin II levels (p=0.04) were associated with increased COVID-19 severity in hypertensive patients, while beta-blockers reduced severity.
Why the study?
The effects of beta-blockers and calcium channel blockers on circulating levels of ACE2 and angiotensin II, as well as COVID-19 severity, were less well studied.
Does the class of antihypertensive medication affect soluble ACE2 and angiotensin II levels and disease severity in hypertensive COVID-19 patients?
Observational (n=200)
Does the class of antihypertensive medication affect soluble ACE2 and angiotensin II levels and disease severity in hypertensive COVID-19 patients?
Different antihypertensive medications are associated with varying levels of soluble ACE2 and angiotensin II, with beta-blockers potentially linked to lower COVID-19 severity.
No takes yet. Share an insight, caveat, or question.
May inform beta-blocker selection in hypertensive COVID-19; leaves open causal effects on ACE2 and outcomes.
Elrayess et al. (2022) conducted an observational in Hypertensive COVID-19 (n=200). Antihypertensive medications (ACEi, ARB, BB, CCB) vs. Comparison between medication classes was evaluated on ACE2 and Angiotensin II levels and their association with COVID-19 severity. Elevated ACE2 (p=0.04 vs mild) and lower angiotensin II levels (p=0.04) were associated with increased COVID-19 severity in hypertensive patients, while beta-blockers reduced severity.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: